The only fully peer reviewed international journal devoted exclusively to lupus (and related disease) research. Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines.
If you wish your article to be freely available online immediately upon publication (as some funding bodies now require), you can opt for it to be included in SAGE Choice upon payment of a publication fee. Manuscript submission and refereeing procedure is unchanged, but on acceptance of your article you will be asked to let SAGE know directly if you are choosing SAGE Choice.
If funding has been provided for your research, convention dictates that you acknowledge the source and grant information in the Acknowledgements section of your article. Please note that in some cases, grant funders require authors to attribute the funding source, describe the role of the study funding body and include the relevant grant reference numbers.
For further information please visit http:/www.sagepub.co.uk/sagechoice.sp
This journal is a member of the Committee on Publication Ethics (COPE).
The only fully peer-reviewed international journal devoted exclusively to lupus (and related disease) research.
Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines.
Invaluable reading, with extended coverage, lupus-related disciplines include:
- Cardiovascular Research
Leading international specialists present their findings on Lupus, in one outstanding reference.
|Maria Laura Bertolaccini||St Thomas' Hospital, UK|
|David D'Cruz||St Thomas' Hospital, UK|
|David Isenberg||University College London, UK|
|Denzil Fletcher||St Thomas' Hospital, UK|
|Graciela Alarcon||The University of Alabama at Birmingham, USA|
|Mary-Carmen Amigo||National Institute of Cardiology, Mexico|
|Tatsuya Atsumi||Hokkaido University Graduate School of Medicine, Japan|
|S. Bombardieri||University of Pisa, Italy|
|D. Boumpas||University of Crete, Greece|
|Jill Buyon||New York University, USA|
|W. Chahade||Sao Paulo, Brazil|
|Shunle Chen||Shanghai Second Medical College, China|
|Charles Christian||University of Florida, USA|
|Rolando Cimaz||University of Milan, Italy|
|Fereydoun Davatchi||Tehran University of Medical Science, Iran|
|R. Derksen||University of Utrecht, Netherlands|
|Andrea Doria||University of Padova|
|Christopher Edwards||Southampton General Hospital, UK|
|Keith Elkon||Cornell Medical College, USA|
|Pao-Hsii Feng||Tan Tock Seng Hospital, Singapore|
|M. Fritzler||University of Calgary, Canada|
|Dr Antonio Gil|
|B. Hahn||University of California, Los Angeles, USA|
|John Hanly||Dalhousie University, Canada|
|E.N. Harris||University of the West Indies, Jamaica|
|E. Hess||University of Cincinnati, USA|
|Frederic Houssiau||Catholic University of Louvain, Belgium|
|O. Hubscher||CEMIC, Argentina|
|Beverley Hunt||St Thomas' Hospital, UK|
|J. Kalden||F.A.-University Erlangen-Nurnberg, Germany|
|C.G. Kallenberg||University Hospital, Netherlands|
|T. Koike||Hokkaido University, Japan|
|S. Krilis||St George Hospital, Australia|
|Vasileios Kyttaris||Beth Israel Medical Center, USA|
|Chak Sing Lau||Queen Mary Hospital, Hong Kong|
|M. Liang||Brigham and Women's Hospital, USA|
|M. Lockshin||Cornell Medical College, USA|
|P Maddison||Gwynedd Rheumatology Services, Wales|
|Pier Luigi Meroni||University of Milan, Italy|
|C C Mok||Hong Kong, China|
|Javier Molina||Health Sciences Institute - CES, Colombia|
|H. Moutsopoulos||University of Athens, Greece|
|A.L. Parke||University of Connecticut Health Cent, USA|
|M. Petri||Johns Hopkins University, USA|
|Jean-Charles Piette||Salpetriere Hospital, France|
|Anisur Rahman||University College London, UK|
|Morris Reichlin||Oklahoma Medical Research Foundation, USA|
|R. Rubin||University of New Mexico, USA|
|Guillermo Ruiz-Irastorza||Hospital de Cruces, Spain|
|Jane E. Salmon||Hospital for Special Surgery, USA|
|P.H. Schur||Brigham and Women's Hospital, USA|
|Yehuda Shoenfeld||Sheba Medical Center, Tel-Hashomer, Israel|
|R. Smeenk||Sanquin Diagnostic Services, The Netherlands|
|J. Smolen||Medical University of Vienna, Austria|
|Richard Sontheimer||University of Iowa, USA|
|Vibeke Strand||Stanford University, USA|
|T. Swaak||Zuiderziekenhuis, Rotterdam, The Netherlands|
|Daniel Tak Mao Chan||University of Hong Kong, Hong Kong|
|Maria Tektonidou||National University of Athens, Greece|
|Dr Lori B Tucker||British Columbia Children's Hospital, Canada|
|M.B. Urowitz||University of Toronto, Canada|
|S Vasoo||Division of Rheumatology, Department of Medicine, National University Hospital, Singapore|
|Daniel J. Wallace||Cedars-Sinai Medical Center, USA|
|Wendell Wilson||Louisiana State University, USA|
|Pierre Youinou||University of Brest, France|
- Article types
- Editorial Policies
2.1 Peer review policy
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical Trials
2.8 Reporting Guidelines
- Publishing Policies
3.1 Publication Ethics
3.2 Contributor's publishing agreement
3.3 Open Access and author archiving
- Preparing your manuscript
4.1 Word processing formats
4.2 Artwork, figures and other graphics
4.3 Supplementary material
4.4 Journal layout
4.5 Reference style
4.6 English language editing services
- Submitting your manuscript
5.1 How to submit your manuscript
5.2 Title, keywords and abstracts
5.3 Corresponding author contact details
- On acceptance and publication
6.1 SAGE Production
6.2 Access to your published article
6.3 Online First publication
- Further Information
This Journal is a member of the Committee on Publication Ethics
This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE)
There are no fees payable to submit or publish in this journal.
Please read the guidelines below then visit the Journal’s submission site http:/mc.manuscriptcentral.com/lupus to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Lupus will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Lupus is published fourteen times a year. The Editor will consider for publication all suitable papers dealing directly or indirectly with lupus or related diseases. The journal includes both clinical and non-clinical research papers. In addition to peer-reviewed (two referees) original papers, the journal also publishes editorials, reports, and letters.
Editorials are solicited by the Editor but suggestions for such material will be very welcome.
GRAND ROUNDS CASES
The purpose of a grand rounds submission is to educate the reader about one or more facets related to the disease lupus or of an autoimmune disease which is related to lupus. A clinicopathological conference can be submitted but this must have postmortem data and is usually a death conference or mortality conference.
Avoid extraneous material which has little bearing on the case at hand. The readers wish to learn about every facet of the case presented and not about other unrelated material.
The submitted case should contain:
Introduction - This should be no more than one or two short paragraphs and summarise what is about to be presented and the reasons why the case was chosen.
Case Presentation - This part contains a succinct narrative of the case itself. Figures, photographs and tables with data are welcome. Also encouraged are data on biopsies with illustrative materials if possible.
Discussion - The discussion should be a focused presentation of theory and/or pathogenetic data regarding the case.
Final Diagnosis - This should be only one sentence which gives the final diagnosis.
These should be short investigative papers and reports organised in the same way as full-length manuscripts but which contain 2000 words or less, with no more than 3 figures or tables and up to 15 references.
The Editor will consider for publication case reports that illustrate points not previously reported in the literature. They should not exceed two printed pages in length. The number of references should not exceed ten.
The number of case reports published will be strictly limited.
LETTERS TO THE EDITOR
Letters to the Editor are encouraged. They may deal with material in published papers or they may raise new issues. Short clinical or laboratory observations may also be presented as Letters.
Letters must contain no more than 500 words, 10 references, 1 table and/or 1 illustration. An abstract is not required and letters should not be divided into sections. Instructions for references, tables and figures are the same as for full length articles.
The journal welcomes the opportunity of publishing supplements to regular issues of significant symposia providing the material represents original work not previously published.
Sponsored symposia should be fully discussed with the Editor prior to agreement to publish.
Faculty, subject matter and editorial content are all subject to the approval of the editorial office and the journal's integrity and reputation should in no way be compromised.
The journal's policy is to obtain at least two independent reviews of each article. Lupus operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations. All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
As part of the submission process you will be asked to provide the names of X peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
2.3.1 Writing Assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Lupus requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Lupus to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations here
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted.
Lupus conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart as a cited figure, and a completed CONSORT checklist as a supplementary file.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Lupus requests all authors submitting any primary data used in their research articles [“alongside their article submissions” or “if the articles are accepted”] to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at Jovie.McMillan@sagepub.co.uk
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway
Lupus and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of articles published in the journal. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked using duplication-checking software. Where an article is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article (removing it from the journal); taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies; banning the author from publication in the journal or all SAGE journals, or appropriate legal action.
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
Lupus offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway
Authors are asked to write their manuscripts in English. Spelling and phraseology should conform either to standard UK English or to standard American English and should be consistent throughout the paper.
The Summary should not exceed 200 words. It should be written in a style that conveys the essential message of the paper in abbreviated form.
The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible.
In the Materials and methods section, methods that have been published in detail elsewhere should not be described in detail. SI units should be used throughout the text.
Tables and figures should be placed after references and not embedded within the text
Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.
Each table should be numbered consecutively with an Arabic numeral. Each should have a separate caption or title. Methods not described in the text and abbreviations should be explained at the foot of the table. Footnotes should be designated by superior lower case letters (a, b, c etc). Vertical lines should not be inserted in the table. Tables must be referred to specifically in the text of the paper.
Lettering should be planned for 50% reduction; text should be readable after reduction. Figures should be referred to as Figure 1, Figure 2 etc. Figures must be referred to specifically in the text of the paper.
Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with a resolution of at least 300 dpi (dots per inch). Line art should be supplied as vector-based, separate .eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a resolution of 600 dpi. Images should be clear, in focus, free of pixilation and not too light or dark.
Colour photographs and Figures - Important information
Colour photographs and Figures, when accepted, will be published online. In the printed version, they will be in black and white (unless colour prints are paid for). Authors who submit in colour must ensure that their figures are of the highest definition for the black and white version otherwise these may not be accepted. In particular dermatological, immuno-fluorescent and histological figures must be paid for in colour or omitted from the manuscript and replaced in a descriptive format. If, together with your accepted article, you submit usable colour figures, these figures will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the possible costs from SAGE after receipt of your accepted article.
The colour printing price is £50 for the first figure and £25 for each figure thereafter.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.
Lupus conforms to the SAGE house style. Click here to review guidelines on SAGE UK House Style.
Lupus adheres to the SAGE Vancouver reference style. Click here to review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
It is important that references comply with the style of the journal. Exhaustive lists should be avoided. References should follow the Vancouver format, listed (double-spaced) in numerical order corresponding to the order of citation in the text.
All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first three only should be quoted followed by et al.
No issue numbers should be quoted.
Abbreviations for titles of medical periodicals should conform to those used in the latest editions of Index Medicus and Current Contents. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such.
Papers in press and papers already submitted for publication may be included in the list of references. No citation is required for work that is not yet submitted for publication.
Personal communications may be allocated a number and included in the list of references in the usual way or simply referred to in the text. Authors must obtain permission from the individual concerned to quote his or her unpublished work.
Examples of References:
1 Derksen RHWM, Bouma BN, Kater L. The association between the lupus anticoagulant and cerebral infarction in systemic lupus erythematosus. Scand J Rheumatol 1986; 15: 179-184.
Journal article, in press:
2 Mendonca LLF, Khamashta MA, Nelson-Piercy A, Hunt BJ, Hughes GRV. Nonsteroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (in press).
Journal article submitted for publication:
3 Khamashta MA, Cervera R, Asherson RA. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus (submitted for publication).
4 Wallace DJ, Dubois EL. Dubois' Lupus Erythematosus. Lea & Febiger, 1987, p 51.
Chapter in book:
5 Christian CL. Etiologic hypotheses for systemic lupus erythematosus. In: Lahita RG (ed) Systemic Lupus Erythematosus. Wiley, 1987, 65-79.
6 Valesini G, Luan FL, Falco M. Clonal analysis of affinity purified anticardiolipin antibodies. Clin Exp Rheumatol 1988; 6: 214 (abstract 102).
Letter to the Editor:
7 Sills EM. Systemic lupus erythematosus in a patient diagnosed as having Shulman disease. Arthritis Rheum 1988; 31: 694 (letter).
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Lupusis hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http:/mc.manuscriptcentral.com/lupus to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Note: Online submission and review of manuscripts is now mandatory for all types of papers.
New User Account
Please log onto the website. If you are a new user, you will first need to create an account. Follow the instructions and please ensure to enter a current and correct email address. Creating your account is a three-step process that takes a matter of minutes. When you have finished, your User ID and password is sent immediately via email. Please edit your user ID and password to something more memorable by selecting 'edit account' at the top of the screen. If you have already created an account but have forgotten your details type your email address in the 'Password Help' to receive an emailed reminder. Full instructions for uploading the manuscript are provided on the website.
Submissions should be made by logging in and selecting the Author Centre and the 'Click here to Submit a New Manuscript' option. Follow the instructions on each page, clicking the 'Next' button on each screen to save your work and advance to the next screen. If at any stage you have any questions or require the user guide, please use the 'Get Help Now' button at the top right of every screen. Further help is available through ScholarOne's® Manuscript Central customer support at +1 434 817 2040 x 167 or email the editor with your manuscript as an attachment(s) and write a note to explain why you need to submit via this route.
To upload your files, click on the 'Browse' button and locate the file on your computer. Select the designation of each file (i.e. main document, submission form, figure) in the drop down menu next to the browse button. When you have selected all the files you wish to upload, click the 'Upload Files' button.
Review your submission (in both PDF and HTML formats) and then click the Submit button
You may suspend a submission at any point before clicking the Submit button and save it to submit later. After submission, you will receive a confirmation e-mail. You can also log back into your author centre at any time to check the status of your manuscript.
Please ensure that you submit editable/source files only (Microsoft Word or RTF) and that your document does not include page numbers; the SAGETRACK system will generate them for you, and then automatically convert your manuscript to PDF for peer review. All correspondence, including notification of the Editor's decision and requests for revisions, will be by email.
If you would like to discuss your paper prior to submission contact the Editor:
Prof. GRV Hughes, email@example.com
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.
SAGE provides authors with online access to their final article.
Online First allows final revision articles (completed articles in queue for assignment to an upcoming issue) to be published online prior to their inclusion in a final journal issue which significantly reduces the lead time between submission and publication. For more information please visit our Online First Fact Sheet
If you would like to discuss your paper prior to submission, please contact the Editor:
Prof. GRV Hughes
Lupus Research Unit
The Rayne Institute
St Thomas' Hospital
London SE1 7EH, UK
Tel: _44 20 7620 2567
Fax: _44 20 7620 2658
Managing Editor: Dr Maria Laura Bertolaccini
Editorial Assistant: Mrs Denzil Fletcher
Contact information for the Publisher: